These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36127739)

  • 21. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
    Declercq J; Bosteels C; Van Damme K; De Leeuw E; Maes B; Vandecauter A; Vermeersch S; Delporte A; Demeyere B; Vuylsteke M; Lalla M; Smart T; Detalle L; Bouw R; Streffer J; Degeeter T; Vergotte M; Guisez T; Van Braeckel E; Van Der Straeten C; Lambrecht BN
    Trials; 2020 Nov; 21(1):934. PubMed ID: 33213529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID).
    Malchair P; Otero A; Giol J; Solanich X; Carnaval T; Fernández-Nistal A; Sánchez-Gabriel A; Montoto C; Lleonart R; Videla S;
    Trials; 2022 Apr; 23(1):303. PubMed ID: 35413921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
    Nickols NG; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Might M; Goldstein DB; Wang X; Ramoni R; Myrie K; Tran S; Ghayouri L; Tsai S; Geelhoed M; Makarov D; Becker DJ; Tsay JC; Diamond M; George A; Al-Ajam M; Belligund P; Montgomery RB; Mostaghel EA; Sulpizio C; Mi Z; Dematt E; Tadalan J; Norman LE; Briones D; Clise CE; Taylor ZW; Huminik JR; Biswas K; Rettig MB
    Trials; 2021 Jul; 22(1):431. PubMed ID: 34225789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial.
    Tomazini BM; Maia IS; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Cavalcanti AB; Rosa RG; Avezum Á; Veiga VC; Lopes RD; Damiani LP; Machado FR; Berwanger O; Azevedo LCP;
    Rev Bras Ter Intensiva; 2020; 32(3):354-362. PubMed ID: 33053024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol.
    Patel B; Mumby S; Johnson N; Falaschetti E; Hansen J; Adcock I; McAuley D; Takata M; Karbing DS; Jabaudon M; Schellengowski P; Rees SE;
    Trials; 2022 Jan; 23(1):47. PubMed ID: 35039050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, Placebo-controlled Trial of Inhaled Treprostinil for Patients at Risk for Acute Respiratory Distress Syndrome.
    Ford HJ; Anderson WH; Wendlandt B; Bice T; Ceppe A; Lanier J; Carson SS
    Ann Am Thorac Soc; 2021 Apr; 18(4):641-647. PubMed ID: 33095030
    [No Abstract]   [Full Text] [Related]  

  • 33. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
    Fragoso-Saavedra S; Iruegas-Nunez DA; Quintero-Villegas A; García-González HB; Nuñez I; Carbajal-Morelos SL; Audelo-Cruz BM; Arias-Martínez S; Caro-Vega Y; Calva JJ; Luqueño-Martínez V; González-Duarte A; Crabtree-Ramírez B; Crispín JC; Sierra-Madero J; Belaunzarán-Zamudio PF; Valdés-Ferrer SI
    BMC Infect Dis; 2020 Oct; 20(1):765. PubMed ID: 33066761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).
    Mariani J; Tajer C; Antonietti L; Inserra F; Ferder L; Manucha W
    Trials; 2021 Feb; 22(1):111. PubMed ID: 33522946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial.
    Schmid B; Kredel M; Ullrich R; Krenn K; Lucas R; Markstaller K; Fischer B; Kranke P; Meybohm P; Zwißler B; Frank S;
    Trials; 2021 Sep; 22(1):643. PubMed ID: 34544463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study.
    Sampley S; Bhasin D; Sekhri K; Singh H; Gupta O
    Indian J Crit Care Med; 2024 Jan; 28(1):70-74. PubMed ID: 38510776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
    Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
    Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.